



(12) Translation of
European patent specification

(11) NO/EP 3210973 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 213/65 (2006.01) A61K 31/4418 (2006.01)

A61K 31/415 (2006.01) A61K 31/505 (2006.01)

A61K 31/421 (2006.01) A61P 27/02 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.03.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.12.02
(86)	European Application Nr.	15853151.7
(86)	European Filing Date	2015.10.22
(87)	The European Application's Publication Date	2017.08.30
(30)	Priority	2014.10.24, JP, 2014217770
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	MA
(73)	Proprietor	Takeda Pharmaceutical Company Limited, 1-1 Doshomachi 4-chome Chuo-ku, Osaka-shi, Osaka 541-0045, Japan
(72)	Inventor	BANNO, Yoshihiro, c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED 26-1 Muraoka-Higashi 2-chome, Fujisawa-shi Kanagawa 251-0012, Japan KAMAURA, Masahiro, c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED 26-1 Muraoka-Higashi 2-chome, Fujisawa-shi Kanagawa 251-0012, Japan TAKAMI, Kazuaki, c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED 26-1 Muraoka-Higashi 2-chome, Fujisawa-shi Kanagawa 251-0012, Japan FUKUDA, Koichiro, c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED 26-1 Muraoka-Higashi 2-chome, Fujisawa-shi Kanagawa 251-0012, Japan SASAKI, Shigekazu, c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED 26-1 Muraoka-Higashi 2-chome, Fujisawa-shi Kanagawa 251-0012, Japan
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54)	Title	HETEROARYL COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES
------	-------	--


(56)	References
------	------------

Cited:	EP-A1- 2 295 406, JP-A- 2012 524 024, WO-A1-2009/051244, JP-A- 2010 540 541, JP-A- 2012 523 461, WO-A1-2009/145286, US-A1- 2012 071 489, WO-A1-2010/120741, WO-A2-03/031984, US-A- 5 371 098
--------	--

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse som er representert ved formelen (I):



hvor

ring A er en pyrazol-ring, en pyridin-ring eller en pyrimidin-ring;

X er CH₂ eller O; og

R er et hydrogen-atom eller en C₁₋₆-alkyl-gruppe, eller et salt derav.

2. Forbindelsen ifølge krav 1, hvor R er en hydrogen-atom, eller et salt derav.

3. En forbindelsen ifølge krav 1, som er ((2-(3,5-bis(trifluormetyl)fenyl)pyrimidin-5-yl)oksi)eddiksyre eller et salt derav.

4. En forbindelsen ifølge krav 1, som er ((6-(3,5-bis(trifluormetyl)fenyl)pyridin-3-yl)oksi)eddiksyre eller et salt derav.

5. En forbindelsen ifølge krav 1, som er 3-(3-(3,5-bis(trifluormetyl)fenyl)-1H-pyrazol-1-yl)propionsyre eller et salt derav.

6. En forbindelsen ifølge krav 1, som er ((1-(3,5-bis(trifluormetyl)fenyl)-1H-pyrazol-3-yl)oksi)eddiksyre eller et salt derav.

7. Et medikament som omfatter forbindelsen ifølge krav 1 eller 2, eller et salt derav.

8. Forbindelsen ifølge krav 1 eller 2, eller et salt derav for bruk i profylakse eller behandling av makulær degenerasjon og/eller Stargardts sykdom.

9. Bruk av forbindelsen ifølge krav 1, eller et salt derav for fremstilling av et profylaktisk eller terapeutisk middel for makulær degenerasjon og/eller Stargardts sykdom.